Combimist L Inhaler: Advanced Dual-Bronchodilation for COPD and Asthma Control
| Product dosage: 50mcg+20mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 2 | $30.12 | $60.23 (0%) | 🛒 Add to cart |
| 3 | $27.11
Best per inhaler | $90.35 $81.32 (10%) | 🛒 Add to cart |
Combimist L Inhaler is a fixed-dose combination inhaler designed for the maintenance treatment of obstructive airway diseases, including chronic obstructive pulmonary disease (COPD) and asthma. It contains Levosalbutamol and Ipratropium Bromide, which work synergistically to provide rapid and sustained bronchodilation. This medication is indicated for patients who require regular bronchodilator therapy to manage symptoms such as wheezing, shortness of breath, and chest tightness. Its metered-dose inhaler (MDI) formulation ensures consistent dosing and portability for on-the-go use.
Features
- Contains Levosalbutamol (50 mcg) and Ipratropium Bromide (20 mcg) per puff
- Delivers 200 metered doses per canister
- Utilizes hydrofluoroalkane (HFA) as a propellant, CFC-free
- Designed with a dose counter for tracking remaining medication
- Compatible with standard spacer devices for improved lung deposition
- Rapid onset of action, typically within 5–15 minutes
- Provides up to 6 hours of bronchodilation per dose
Benefits
- Enhanced bronchodilation: Dual-mechanism action targets both beta-2 adrenergic receptors and muscarinic receptors for comprehensive airway relaxation.
- Improved symptom control: Reduces the frequency and severity of exacerbations in COPD and asthma patients.
- Increased exercise tolerance: Allows for better physical activity by alleviating breathlessness and wheezing.
- Convenient dosing regimen: Combines two bronchodilators in a single inhaler, simplifying medication management.
- Reduced rescue medication use: Effective maintenance therapy decreases the need for short-acting relievers.
- Suitable for long-term use: Well-tolerated profile supports adherence to chronic treatment plans.
Common use
Combimist L Inhaler is primarily prescribed for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis. It is also used in the management of asthma, particularly in cases where symptoms are not adequately controlled by a single bronchodilator. This inhaler is intended for regular use to prevent bronchospasm and improve lung function over time. It is not recommended for the treatment of acute bronchospasm episodes, for which a fast-acting reliever inhaler should be used instead.
Dosage and direction
The typical dosage for adults and adolescents over 12 years is two puffs, taken two to four times daily, or as directed by a healthcare provider. Shake the inhaler well before each use. Exhale fully away from the mouthpiece, place the lips tightly around it, and inhale deeply and slowly while pressing down on the canister. Hold your breath for 10 seconds to allow the medication to deposit in the airways. Wait at least 30 seconds before administering a second puff, if required. Rinse the mouth with water after each use to minimize the risk of oral thrush. Do not exceed the prescribed dosage without medical consultation.
Precautions
- Use with caution in patients with cardiovascular disorders, such as hypertension, arrhythmias, or ischemic heart disease, due to potential sympathetic stimulation.
- Monitor patients with narrow-angle glaucoma or prostatic hyperplasia, as anticholinergic agents may exacerbate these conditions.
- Avoid use in individuals with hypersensitivity to any component of the formulation or similar bronchodilators.
- Not recommended during pregnancy or lactation unless the potential benefits outweigh the risks; consult a physician.
- Elderly patients may require dose adjustments based on renal or hepatic function.
- Regularly assess pulmonary function and symptom control to ensure therapeutic efficacy.
Contraindications
Combimist L Inhaler is contraindicated in patients with a known hypersensitivity to Levosalbutamol, Ipratropium Bromide, or any other ingredient in the formulation. It should not be used in individuals with a history of tachyarrhythmias or severe cardiac disease. Avoid in patients with untreated narrow-angle glaucoma or bladder neck obstruction. This medication is not indicated for the initial treatment of acute bronchospasm.
Possible side effect
Common side effects may include dry mouth, headache, tremor, nervousness, dizziness, cough, and palpitations. Less frequently, patients may experience nausea, blurred vision, urinary retention, or paradoxical bronchospasm. Allergic reactions such as rash, itching, or angioedema are rare but require immediate medical attention. Long-term use at high doses may lead to hypokalemia or increased blood glucose levels. Report any persistent or severe adverse effects to a healthcare provider.
Drug interaction
Combimist L Inhaler may interact with other adrenergic drugs, such as beta-blockers (e.g., propranolol), which can antagonize its effects. Concurrent use with other anticholinergic agents may increase the risk of side effects like dry mouth and urinary retention. Diuretics or corticosteroids can potentiate hypokalemia. Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants may enhance the cardiovascular effects of Levosalbutamol. Always inform your doctor of all medications, including over-the-counter drugs and supplements.
Missed dose
If a dose is missed, take it as soon as remembered, unless it is almost time for the next scheduled dose. Do not double the dose to make up for a missed one. Maintain the regular dosing schedule to ensure consistent bronchodilation. If unsure, consult your physician or pharmacist for guidance.
Overdose
Overdose may manifest as exaggerated pharmacological effects, including tachycardia, hypertension, tremors, angina, hypokalemia, and nausea. In severe cases, seizures or cardiac arrest may occur. Treatment is supportive and symptomatic; consider activated charcoal if ingestion is recent. Beta-blockers may be used to counteract adrenergic effects, but caution is advised in patients with asthma due to the risk of bronchoconstriction. Seek immediate medical attention in case of suspected overdose.
Storage
Store at room temperature (15–30°C), away from direct sunlight, moisture, and heat. Do not puncture or incinerate the canister, even when empty. Keep out of reach of children and pets. The inhaler should be discarded after the specified number of doses or by the expiration date, whichever comes first.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider for diagnosis, treatment decisions, and personalized recommendations. The manufacturer and distributor are not liable for any misuse or adverse outcomes resulting from the application of this information.
Reviews
“After switching to Combimist L, my COPD symptoms have been much better controlled. I use it twice daily and have noticed a significant reduction in rescue inhaler use.” – Patient, 64 years
“As a pulmonologist, I find Combimist L effective for patients with moderate to severe COPD who need dual bronchodilation. The combination improves compliance and outcomes.” – Dr. A. Sharma, MD
“Easy to use and portable. The dose counter is helpful for tracking, though I occasionally experience a dry mouth, which is manageable with water rinsing.” – Patient, 52 years
“Clinical studies support the efficacy of Levosalbutamol and Ipratropium in combination for improving FEV1 and quality of life in obstructive airway diseases.” – Clinical Pharmacist Review